Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMRA-335140 OLE in Major Depressive Disorder
NCT06029439Phase 3Terminated
- Sponsor
- Neumora Therapeutics, Inc.
- Start
- Nov 2023
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of navacaprant in major depressive disorder (MDD), sponsored by Neumora Therapeutics, Inc.. Started Nov 2023; status: terminated.
02
Drugs
navacaprant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06029439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06029439.